Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of newly diagnosed pediatric diffuse intrinsic pontine glioma (dipg)
Xiaoguang Qiu,Mawei Jiang,Chao Liu,Gang Wang,Rongjie Tao,Jiankun Xu,Liangfang Shen,Yanwei Liu,Heling Wang,Chuanying Zhu,Hui Zhang,Gao Zeng,Jidong Hong,Baoshi Chen,Shujun Wang,Wenlan Bao,Jia Yang,Qingtang Lin,Huan Li,Shuai Liu,Wei Zhang,Shuxian Chen,Yongrui Zhao,Jianbing Tang,Zhen Kou,Jun Su,Peng Sun,Longyun Wang,Xiaoyang Sun,Yan Ju,Wenbin Ma,Yu Wang
DOI: https://doi.org/10.1093/neuonc/noad179.0302
2023-01-01
Neuro-Oncology
Abstract:Abstract BACKGROUND Newly diagnosed pediatric DIPG is a fetal disease with a poor prognosis and lacks of effective treatments. Multiple studies have demonstrated that the median survival time for patients is less than one year. A single-armed, prospective, multicenter study was conducted to evaluate the efficacy and safety of adding nimotuzumab to concurrent chemoradiotherapy for the treatment of newly diagnosed pediatric DIPG. METHODS Patients were 3-15 years old, histologically or imaging confirmed newly diagnosed DIPG, Lansky score ≥ 60, and at least one measurable lesion. Totally 48 patients were enrolled. Nimotuzumab (150mg/m2/w) concurrent chemoradiotherapy (Temozolomide: 75mg/m2 per day. Radiotherapy: 54Gy/30f) were administered for 6 weeks following a maintenance treatment (Nimotuzumab: 150mg/m2 biweekly. Temozolomide: 150-200mg/m2 per day for 5 days every 28 day). The primary endpoint was ORR, with secondary endpoints including 1-year OS rate, PFS and safety. RESULTS Between Apr 3, 2021 and Apr 13, 2023, a total of 48 patients were enrolled with a median age of 7 years old, in which 20 patients radiologically diagnosed DIPG, 28 patients histopathologically confirmed DIPG with 25 (89.3%) had H3K27M mutation. The median follow-up was 15.2 months. The ORR was 31.3% (95%CI, 18.66%-46.25%), mOS was 10.35 months, 1-year OS rate was 27.4% (95%CI, 14.73%-41.73%), mPFS was 6.93 months, and 1-year PFS was 9.5% (95%CI, 2.46%-22.56%). Eight patients (16.7%) experienced grade 3 or above ADRs. The most common toxicities were neutropenia (40%), leukopenia (25.0%), thrombocytopenia (25.0%). anemia (5.0%), flank pain (5.0%). CONCLUSIONS Nimotuzumab combined with concurrent chemoradiotherapy showed survival benifit for newly diagnosed pediatric DIPG patients with tolerable toxicity.